Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Shareholder Meeting (May 2021)
25 slides from Elixinol Wellness's shareholder meeting presentation, May 17, 2021
Slide 1: Annual General Meeting May 2021
For personal use only ASX:EXL | OTCQB:ELLXF Annual General Meeting May 2021 This document was authorised to be given to the ASX by the Board of the Company. Let Nature Shine 1
Slide 2: Disclaimer
Annual General Meeting – May 2021 Disclaimer For personal use only This presentation contains summary information about Elixinol Global Limited (Elixinol) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction
Slide 3: CEO update
Annual General Meeting – May 2021 CEO update For personal use only Oliver Horn Let Nature Shine 3
Slide 4: Elixinol CBD: Our Vision and Mission
Annual General Meeting – May 2021 Elixinol CBD Our Vision For personal use only Building a global, natural health and wellness consumer products business. elixinolSkin CBD Our Mission Making a positive contribution to people’s health, wellness and the planet through the power of hemp and natural pro
Slide 5: Our year of transformation in review
Annual General Meeting – May 2021 Our year of transformation in review For personal use only • +18% growth on prior • Good Mood CBD quarter gummies launch • Tighter COVID restrictions • Board + Management team changes – Oliver • UK drives growth with new • COVID-19 continues to • CannaCare acquisiti
Slide 6: Rebranding to Elixinol Wellness
For personal use only Annual General Meeting – May 2021 We’ve been a wellness company all along. Rebranding ourselves to Elixinol Wellness is a natural yet symbolic step in our journey of creating a global wellness consumer products business that makes a positive contribution to people’s health, wel
Slide 7: FY2020 financial summary
Annual General Meeting – May 2021 FY2020 financial summary For personal use only Well funded, reduced cost base and refocused on building a profitable consumer goods business. Annualised cost base 45% Substantial operational and corporate cost reduction program completed in June 2020. Well funded* C
Slide 8: Key highlights of Q1 FY2021
Annual General Meeting – May 2021 Key highlights of Q1 FY2021 For personal use only Whilst Q1 results have been impacted by COVID restrictions and seasonality, we’ve seen a gradual revenue improvement month over month, improved gross margins, further reduced cost and advanced our digital-first agend
Slide 9: Elixinol brand health US
Annual General Meeting – May 2021 Elixinol brand health US For personal use only Elixinol is perceived as a high quality and effective brand that compares favourably against the market leader. The brand relaunch and re-positioning has materially improved the brand’s brand health metrics and is seen
Slide 10: Evolved brand positioning
Annual General Meeting – May 2021 Evolved brand positioning For personal use only To create stronger emotional engagement with consumers, Elixinol will launch the ‘Let Nature Shine campaign’ connecting our heritage of sourcing the best from nature through hemp with today’s consumers’ need for natura
Slide 11: Growth through innovation
Annual General Meeting – May 2021 Growth through innovation For personal use only We’ve developed our portfolio across all regions to improve our product offering, attract new customers and ‘premiumise’ our brands. Let Nature Shine 11
Slide 12: Digital strategy driving results across all regions
Annual General Meeting – May 2021 Digital strategy driving results across all regions For personal use only Investment in digital and e-commerce capability is showing positive results across all business units. Revenues from e-commerce in Q1 accounted for 40% of total Group revenues compared to 33%
Slide 13: Welcoming agents of change & new leaders
Annual General Meeting – May 2021 Welcoming agents of change & new leaders For personal use only Let Nature Shine 13
Slide 14: Global CBD market outlook & regulations
Annual General Meeting – May 2021 Global CBD market outlook & regulations For personal use only The global CBD is projected for sustained long-term growth. Regulations are changing fast and in favour of CBD but will create transitionary volatility. Gradual recovery from COVID restrictions and indust
Slide 15: Proposed acquisition of CannaCare Health
For personal use only Annual General Meeting – May 2021 ASX:EXL | OCTQB:ELLXF Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business Announced on 15 March 2021 Let Nature Shine Let Nature Shine 15
Slide 16: CannaCare overview
Annual General Meeting – May 2021 CannaCare overview For personal use only CannaCare presents an opportunity to take a significant share of Europe’s fastest growing CBD market. • Established 2018, • Extensive product • CANOBO #1 brand • CANOBO first • Capital light model • Strict quality • New cosme
Slide 17: Early skincare success
Annual General Meeting – May 2021 Early skincare success For personal use only Skincare range launch in April achieved extensive distribution and early re-orders. Canobo skincare is Mueller’s best selling new cosmetic line. Extensive integrated media campaign results • Press coverage to-date: 14.5m
Slide 18: Synergies and growth outlook
Annual General Meeting – May 2021 Synergies and growth outlook For personal use only An acquisition of CannaCare will deliver Elixinol immediate material scale in Germany, while creating significant long-term value through a high growth market trend, identified cost synergies and potential cross-sel
Slide 19: Key people
Annual General Meeting – May 2021 Key people For personal use only FRANK OTTO OLIVER HAIST Strategy Partner & Shareholder Managing Director Serial founder in the media industry L’Oréal – Group Key Account Manager FMCG Founder and investor of many successful Philips – International Head of Sales FMCG
Slide 20: Transaction summary
Annual General Meeting – May 2021 Transaction summary For personal use only Elixinol plans to acquire leading German-based CBD business, CannaCare with acquisition expected to fast-track revenue growth and accelerate pathway to group profitability Attractive, EBITDA accretive acquisition • Up-front
Slide 21: Performance since March
Annual General Meeting – May 2021 Performance since March For personal use only CannaCare’s performance in Germany has been consistent with our expectations, supported by a successful skincare launch The combination of CannaCare with Elixinol’s UK business is expected to create an In Q1 FY2021 Canna
Slide 22: Timetable
Annual General Meeting – May 2021 Timetable For personal use only Event Date Despatch of Notice Of Meeting to shareholders Thursday, 15 April 2021 (including Independent Expert’s Report) Annual General Meeting Monday, 17 May 2021 Targeted transaction completion Monday, 5 July 2021 Issue of Upfront C
Slide 23: What's next
Annual General Meeting – May 2021 What’s next… For personal use only Our core priorities are to re-ignite our US and UK businesses following severe COVID restrictions, integrate CannaCare into the Elixinol Group whilst fuelling the Canobo growth, further shifting our business to digital and optimise
Slide 24: In summary
Investor Presentation – May 2021 In summary…the new For personal use only Our brands are Continued Well positioned strong and business in global CBD getting stronger transformation in markets repositioning and a better economic with new scale in innovation is leading environment, with high growth Eu
Slide 25: For more information
For personal use only Annual General Meeting – May 2021 For more information Investor relations and media please contact: Ron Dufficy, Global CFO ron.dufficy@elixinolglobal.com Let Nature Shine 25